MADRIGAL PHARMACEUTICALS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 17.64K shares, a 4.01% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 58.81K shares, a 41.35% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 114.18K shares, a 36.80% decline year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 448.30K shares, a 488.35% increase year-over-year.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 681.13K shares, a 26.67% decline from fiscal 2024.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 928.80K shares, a 101.74% increase from fiscal 2023.
- MADRIGAL PHARMACEUTICALS, INC. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 460.38K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 17.64K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-30 | 638.93K shares derived: sum of 4 quarters · filed 2026-07-30 |
| 2026-03-31 | 58.81K shares 10-Q · filed 2026-05-06 | 639.67K shares derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | 114.18K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | 681.13K shares 10-K · filed 2026-02-19 |
| 2025-09-30 | 448.30K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | 747.61K shares derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | 18.38K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | 375.51K shares derived: sum of 4 quarters · filed 2025-08-05 |
| 2025-03-31 | 100.28K shares 10-Q · filed 2025-05-01 | 1.01M shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | 180.66K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | 928.80K shares 10-K · filed 2025-02-26 |
| 2024-09-30 | 76.20K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | |
| 2024-06-30 | 653.63K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | |
| 2024-03-31 | 18.32K shares 10-Q · filed 2024-05-07 | |
| 2023-12-31 | 460.38K shares 10-K · filed 2024-02-28 | |
| 2019-03-31 | 83.00 shares 10-Q · filed 2020-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |